178 related articles for article (PubMed ID: 7564356)
1. Cardioprotection with the KATP opener cromakalim is not correlated with ischemic myocardial action potential duration.
Grover GJ; D'Alonzo AJ; Parham CS; Darbenzio RB
J Cardiovasc Pharmacol; 1995 Jul; 26(1):145-52. PubMed ID: 7564356
[TBL] [Abstract][Full Text] [Related]
2. Effects of the KATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs.
Yao Z; Gross GJ
Circulation; 1994 Apr; 89(4):1769-75. PubMed ID: 8149542
[TBL] [Abstract][Full Text] [Related]
3. Preconditioning is not abolished by the delayed rectifier K+ blocker dofetilide.
Grover GJ; D'Alonzo AJ; Dzwonczyk S; Parham CS; Darbenzio RB
Am J Physiol; 1996 Sep; 271(3 Pt 2):H1207-14. PubMed ID: 8853361
[TBL] [Abstract][Full Text] [Related]
4. Activation of ATP-sensitive K+ channels by cromakalim. Effects on cellular K+ loss and cardiac function in ischemic and reperfused mammalian ventricle.
Venkatesh N; Stuart JS; Lamp ST; Alexander LD; Weiss JN
Circ Res; 1992 Dec; 71(6):1324-33. PubMed ID: 1423930
[TBL] [Abstract][Full Text] [Related]
5. Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening.
Grover GJ; D'Alonzo AJ; Hess T; Sleph PG; Darbenzio RB
Cardiovasc Res; 1995 Nov; 30(5):731-8. PubMed ID: 8595620
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological evidence for the persistent activation of ATP-sensitive K+ channels in early phase of reperfusion and its protective role against myocardial stunning.
Shigematsu S; Sato T; Abe T; Saikawa T; Sakata T; Arita M
Circulation; 1995 Oct; 92(8):2266-75. PubMed ID: 7554211
[TBL] [Abstract][Full Text] [Related]
7. Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448.
Grover GJ; McCullough JR; D'Alonzo AJ; Sargent CA; Atwal KS
J Cardiovasc Pharmacol; 1995 Jan; 25(1):40-50. PubMed ID: 7723352
[TBL] [Abstract][Full Text] [Related]
8. KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide.
Ferdinandy P; Szilvássy Z; Droy-Lefaix MT; Tarrade T; Koltai M
Cardiovasc Res; 1995 Nov; 30(5):781-7. PubMed ID: 8595627
[TBL] [Abstract][Full Text] [Related]
9. KATP channel modulators increase survival rate during coronary occlusion-reperfusion in anaesthetized rats.
Baczkó I; Leprán I; Papp JG
Eur J Pharmacol; 1997 Apr; 324(1):77-83. PubMed ID: 9137916
[TBL] [Abstract][Full Text] [Related]
10. Adenosine triphosphate-sensitive potassium channel blocking agent ameliorates, but the opening agent aggravates, ischemia/reperfusion-induced injury. Heart function studies in nonfibrillating isolated hearts.
Tosaki A; Hellegouarch A
J Am Coll Cardiol; 1994 Feb; 23(2):487-96. PubMed ID: 8294705
[TBL] [Abstract][Full Text] [Related]
11. Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies.
Docherty JC; Gunter HE; Kuzio B; Shoemaker L; Yang L; Deslauriers R
J Mol Cell Cardiol; 1997 Jun; 29(6):1665-73. PubMed ID: 9220352
[TBL] [Abstract][Full Text] [Related]
12. Protective effects of ATP-sensitive potassium-channel openers in experimental myocardial ischemia.
Grover GJ
J Cardiovasc Pharmacol; 1994; 24 Suppl 4():S18-27. PubMed ID: 7898104
[TBL] [Abstract][Full Text] [Related]
13. The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanism.
Grover GJ; D'Alonzo AJ; Sleph PG; Dzwonczyk S; Hess TA; Darbenzio RB
J Pharmacol Exp Ther; 1994 May; 269(2):536-40. PubMed ID: 8182522
[TBL] [Abstract][Full Text] [Related]
14. Bimakalim, an ATP-sensitive potassium channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs.
Mizumura T; Nithipatikom K; Gross GJ
Circulation; 1995 Sep; 92(5):1236-45. PubMed ID: 7648671
[TBL] [Abstract][Full Text] [Related]
15. Effects of intracoronary cromakalim on postischaemic contractile function and action potential duration.
D'Alonzo AJ; Darbenzio RB; Parham CS; Grover GJ
Cardiovasc Res; 1992 Nov; 26(11):1046-53. PubMed ID: 1291081
[TBL] [Abstract][Full Text] [Related]
16. Effects of cromakalim or pinacidil on pacing- and ischemia-induced ventricular fibrillation in the anesthetized pig.
D'Alonzo AJ; Hess TA; Darbenzio RB; Sewter JC; Conder ML; McCullough JR
Basic Res Cardiol; 1994; 89(2):163-76. PubMed ID: 8074640
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial K ATP channel activation is important in the antiarrhythmic and cardioprotective effects of non-hypotensive doses of nicorandil and cromakalim during ischemia/reperfusion: a study in an intact anesthetized rabbit model.
Das B; Sarkar C
Pharmacol Res; 2003 Jun; 47(6):447-61. PubMed ID: 12741997
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of KATP channel-opener induced shortening of repolarization time by alpha 1-adrenoceptor antagonist during ischemia in canine heart.
Tanabe T; Aikawa M; Deguchi Y; Yoshioka K; Handa S
Cardiovasc Drugs Ther; 2000 Jun; 14(3):283-94. PubMed ID: 10935150
[TBL] [Abstract][Full Text] [Related]
19. The effects of a newly synthesized ATP-sensitive potassium channel opener, MJ-355, on blood pressure and myocardial ischemia-reperfusion injury in rats.
Lee YM; Peng YY; Sheu JR; Cheng CY; Yen MH
Jpn J Pharmacol; 1999 Oct; 81(2):185-93. PubMed ID: 10591476
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotective effects of NIP-121, a novel ATP-sensitive potassium channel opener, during ischemia and reperfusion in coronary perfused guinea pig myocardium.
Tanaka H; Okazaki K; Shigenobu K
J Cardiovasc Pharmacol; 1996 May; 27(5):695-701. PubMed ID: 8859940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
